Invesco Ltd. Verve Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 54,060 shares of VERV stock, worth $275,165. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,060

Previous 55,031 1.76%

Holding current value

$275,165

Previous $268,000 2.61%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$4.4 - $7.86 $4,272 - $7,632	-971 Reduced 1.76%	54,060 $261,000
Q2 2024 Aug 13, 2024	SELL	$4.76 - $12.79 $10,143 - $27,255	-2,131 Reduced 3.73%	55,031 $268,000
Q1 2024 May 14, 2024	BUY	$10.81 - $17.96 $336,666 - $559,346	31,144 Added 119.7%	57,162 $759,000
Q4 2023 Feb 12, 2024	BUY	$8.84 - $18.7 $51,802 - $109,582	5,860 Added 29.07%	26,018 $362,000
Q3 2023 Nov 13, 2023	SELL	$11.42 - $20.82 $1,153 - $2,102	-101 Reduced 0.5%	20,158 $267,000
Q2 2023 Aug 11, 2023	SELL	$13.34 - $19.9 $24,305 - $36,257	-1,822 Reduced 8.25%	20,259 $379,000
Q1 2023 May 12, 2023	BUY	$14.3 - $24.01 $83,268 - $139,810	5,823 Added 35.82%	22,081 $318,000
Q4 2022 Feb 13, 2023	SELL	$17.85 - $40.7 $2.66 Million - $6.06 Million	-148,918 Reduced 90.16%	16,258 $314,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $2.38 Million - $6.31 Million	152,057 Added 1159.06%	165,176 $5.67 Million
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $35,870 - $74,607	3,220 Added 32.53%	13,119 $201,000
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $54,517 - $102,572	2,606 Added 35.73%	9,899 $226,000
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $64,646 - $110,955	2,024 Added 38.41%	7,293 $269,000
Q3 2021 Nov 15, 2021	BUY	$46.0 - $73.99 $242,374 - $389,853	5,269 New	5,269 $248,000

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $305M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account